Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of a highly potent and selective degrader of LRRK2.

Bioorganic & medicinal chemistry letters - 1 Oct 2023

Hatcher John M, Zwirek Monika, Sarhan Adil R, Vatsan Prasanna S, Tonelli Francesca, Alessi Dario R, Davies Paul, Gray Nathanael S

Abstract excerpt

The discovery of disease-modifying therapies for Parkinson's Disease (PD) represents a critical need in neurodegenerative medicine. Genetic mutations in leucine-rich repeat kinase 2 (LRRK2) are risk factors for the development of PD, and some of these mutations have been linked to increased LRRK2 kinase activity and neuronal toxicity in cellular and animal models. Furthermore, LRRK2 function as a scaffolding...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
Share to Models, Animal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Parkinson Disease

Share to Phosphorylation

Source

Identifiers

PMID: 37591317
DOI: 10.1016/j.bmcl.2023.129449

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of a highly potent and selective degrader of LRRK2.PMID 37591317Read ↗

LRRK2 PROTAC Degraders as a Potential Novel Targeting Strategy for Parkinson's Disease?Semantic proximity Read ↗

Breaking Bad Proteins – Discovery Approaches and the Road to Clinic for DegradersSemantic proximity Read ↗

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.Semantic proximity Read ↗

PROTAC’ing oncoproteins: targeted protein degradation for cancer therapySemantic proximity Read ↗

PROTACs: great opportunities for academia and industrySemantic proximity Read ↗

Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson’s disease: a patent review of the literature to dateSemantic proximity Read ↗

Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1.Semantic proximity Read ↗

Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).Semantic proximity Read ↗

Catalyzing a Cure: Discovery and development of LRRK2 inhibitors for the treatment of Parkinson's disease.Semantic proximity Read ↗

FDA-approved kinase inhibitors in PROTAC design, development and synthesisSemantic proximity Read ↗

Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade.Semantic proximity Read ↗

Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.